Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

If you've been diagnosed with multiple sclerosis (MS), it's time to start exploring treatment options. You've got a lot of them, everything from disease-modifying therapies and drugs that help manage ...

Axon Enterprise, Inc. (NASDAQ:AXON), a leader in public safety technology with a market capitalization of over $50 billion, has been on a remarkable growth trajectory, driven by its expanding product ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Heterogeneous nuclear ribonucleoproteins (hnRNPs) constitute a family of multifunctional RNA-binding proteins able to process nuclear pre-mRNAs into mature mRNAs and regulate gene expression in ...

In particular, Rho GTPases regulate dendritic arborization, spine morphogenesis, growth cone development, and axon guidance ... of neurodegenerative disease such as amyotrophic lateral sclerosis.

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...